Thyroid Disease in Pregnancy: Case Finding Versus Universal Screening

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00846755
Recruitment Status : Completed
First Posted : February 19, 2009
Last Update Posted : September 27, 2011
Information provided by (Responsible Party):
Dr. Roberto Negro, Ospedale V. Fazzi

Brief Summary:
The purpose of this study is to determine whether treatment of thyroid disease during pregnancy decrease the incidence of adverse outcome, and to compare the impact of Universal Screening versus case Finding strategy in detecting thyroid dysfunction

Condition or disease Intervention/treatment Phase
Thyroid Disease Pregnancy Drug: Levothyroxine, Propylthiouracile Not Applicable

Detailed Description:
Thyroid disease during pregnancy has been associated with multiple adverse outcomes including miscarriage, preterm delivery, postpartum thyroiditis and decreased IQ in the offspring. Whether or not all women should be screened for thyroid disease during pregnancy (Universal Screening), screening should be confined to women at high risk for thyroid disease (Case Finding), or no screening should occur is controversial. For this purpose, pregnant women in the first trimester are randomly assigned to the Screening group or Case finding group. All women in the Screening group and high-risk women in the Case Finding group are immediately tested for FT4, TSH and TPO antibodies. Low-risk women in the Case Finding group have their sera tested postpartum. levothyroxine or PTU are given in hypothyroid and hyperthyroid women respectively. Outcome Measure: total number of adverse events occurring during pregnancy and in the neonatal period controlling for clustering of outcomes within women.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4657 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Impact of Treating Thyroid Hormone Dysfunction During Pregnancy: A Randomized Controlled Trial of Universal Screening Versus Case Finding
Study Start Date : March 2005
Actual Primary Completion Date : March 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Thyroid Diseases

Arm Intervention/treatment
Active Comparator: Levothyroxine, Propylthiouracil
Drugs for the treatment of thyroid disease, are administered, when necessary, in high risk women, either in case finding, or in Universal Screening Group
Drug: Levothyroxine, Propylthiouracile
Drugs were titrated to render euthyroid pregnant patients with thyroid disease
Other Names:
  • Levothyroxine
  • Propylthiouracile

No Intervention: clinical checks
Low risk women whose sera are tested postpartum. Then patients with undiagnosed thyroid disease, are not treated

Primary Outcome Measures :
  1. number of adverse outcomes which occur during pregnancy and in the neonatal period in patients divided in Case Finding and Universal Screening groups [ Time Frame: 9 months ]

Secondary Outcome Measures :
  1. Evaluation of the efficacy of Case Finding and Screening strategy [ Time Frame: 4 years ]
  2. Intelligence Quotient [ Time Frame: 6 years ]
    •Intellectual function of children at 6 years of age, as measured by the Wechsler Intelligence Scale for Children (WISC) III, in women with a)hypothyroidism, left untreated because belonging to Case Finding Low Risk Group, b) hypothyroidism, treated with levothyroxine because belonging to Universal Screening High Risk and Low Risk Groups, and in Case Finding High Risk Group, and c)euthyroidism (control group)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Pregnant women
  • Within 11 week of gestation

Exclusion Criteria:

  • Already known thyroid disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00846755

"V. Fazzi" Hospital
Lecce, Italy, 73100
Sponsors and Collaborators
Ospedale V. Fazzi
Principal Investigator: Roberto Negro, Dr "V. Fazzi" Hospital

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Dr. Roberto Negro, MD, Ospedale V. Fazzi Identifier: NCT00846755     History of Changes
Other Study ID Numbers: LE-1126-IT
First Posted: February 19, 2009    Key Record Dates
Last Update Posted: September 27, 2011
Last Verified: September 2011

Keywords provided by Dr. Roberto Negro, Ospedale V. Fazzi:

Additional relevant MeSH terms:
Thyroid Diseases
Endocrine System Diseases
Molecular Mechanisms of Pharmacological Action
Antithyroid Agents
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs